Current Studies

 

CURRENTLY ENROLLING STUDIES

 

 

Ages 50-85

A Phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate theefficiencyy and safety of Aducanumab (BIIB037) in subjects with early Alzheimer’s Disease (AD), mild cognitive impairment (MCI) due to AD and a subset of mild AD (per NIA-AA guidelines). Subjects will undergo brain MRI, PET scan (subset of subjects), optional CSF Biomarker and series of clinical assessments. Total duration of study participation is 102 weeks for the placebo-controlled period and 206 weeks for subjects participating in Long-term Extension (LTE). Subjects will receive infusions of aducanumab or placebo approx. every 4 weeks for approx. 18 months (20 doses total).

More Information

 

 

Ages 55-85

No Seasonal Transfers Allowed

A Phase 2, multicenter, multiple dose, randomized, double-blind, placebo-controlled study of ABBV-8E12 in patients with Early Alzheimer’s Disease (Mild Cognitive Impairment/ Mild Alzheimer’s Disease) per NIA-AA clinical criteria. Subjects will undergo brain MRI, PET Scan, lumbar puncture, cognitive testing, physical and neurological examinations. Study participation consists of a 96-week treatment period with infusions every 4 weeks. Subjects that complete the 96-week treatment period may enter a separate extended treatment study if eligible.

More Information

 

 

Ages 50-80

No Seasonal Transfers Allowed

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Efficacy, and Safety Study of MTAU9937A in Patients with Prodromal to Mild Alzheimer’s Disease. Subjects will undergo brain MRI, amyloid PET and/or Lumbar Puncture, Tau PET, cognitive testing, physical and neurological examinations. Study participation consists of a 73 week treatment period of infusions every 2 weeks for the first three doses and every 4 weeks thereafter. Participants may enter an additional Open Label Extension period (92 weeks) if eligible upon completion of double blind treatment phase.

More Information

 

 

 

Ages 50-80

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease or with Mild Alzheimer’s Disease. Subjects will undergo brain MRI, Amyloid and Tau PET, cognitive testing, physical and neurological examinations, optional Lumbar Puncture. Study participation consists of a screening period of up to 9 weeks, a 76-week infusion treatment period, an End of Study visit, and follow up safety visit 14 weeks after last study dose treatment.

More Information

 

 

Ages 60-85

Diagnostic PET Scan Trial

A phase II, Multicenter, screening study with flortaucipir F18 in patients with early symptomatic AD defined as prodromal AD and mild dementia due to AD. Subjects will have expressed preliminary interest in Lilly AD therapeutic trials similar to the LMDC trial (More Information), however consent for this trial does not constitute consent for any Lilly AD trial. Subjects will undergo vital signs, cognitive testing, ECG, and flortaucipir F18 scan. Screening may take place over sever days with all screening assessments performed within 30 days prior to flortaucipir injection.

More Information

 

Ages 60-85

No Seasonal Transfers Allowed

A Phase II, Randomized, Double-Blind, Placebo-Controlled, study of LY3303560 in subjects with early symptomatic AD with low-to-medium cerebral tau burden. Subjects will undergo brain MRI, Tau (Flortaucipir F18) PET scan, cognitive testing, physical and neurological examinations. Study participation consists of a screening period up to 8 weeks, a 76-week infusion treatment period and a 4-week safety follow up period.

More Information

 

 

 

 

 

 

 

 

Neuropsychiatric Research Center of Southwest Florida

14271 Metropolis Avenue, Suite A • Fort Myers, FL  33912